YP
MTNB icon

Yellowstone Partners’s Matinas BioPharma MTNB Stock Holding History

Yellowstone Partners’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$167K Hold
2,878
– – 0.09% 165
2017
Q3 		$190K Buy
+2,878
New +$192K 0.1% 180

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWMG
Alliance Wealth Management Group Flemington, New Jersey $457M AUM 12.13% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Yellowstone Partners's MTNB Position: Q4 2017 in Review

Yellowstone Partners held its Matinas BioPharma (MTNB) position steady in Q4 2017 at 2,878 shares worth $167K. The position accounts for 0.09% of the portfolio, ranked #165.

Yellowstone Partners first reported a position in MTNB in Q3 2017 and has held it in 2 quarters since. The position peaked at $190K in Q3 2017. 49 funds tracked by Wall St. Rank hold MTNB as of Q4 2017.

  • Yellowstone Partners held 2,878 shares of Matinas BioPharma worth $167K as of Q4 2017.
  • Yellowstone Partners left its Matinas BioPharma share count unchanged in Q4 2017.
  • Matinas BioPharma made up 0.09% of Yellowstone Partners's portfolio in Q4 2017, its #165 holding.
  • Yellowstone Partners first reported a position in Matinas BioPharma in Q3 2017 and has held it in 2 quarters since.
  • Yellowstone Partners's Matinas BioPharma position peaked at $190K in Q3 2017.
  • 49 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2017.

Based on Yellowstone Partners's 13F filing for Q4 2017, filed 24 Jan 2018.